Extract to table

Graystone University Medical Center is designated as Site 001 in Schedule 1 to the Agreement and shall serve as the lead clinical site for the conduct of Protocol PPC-4871-III (the "CLARION" trial) within the Veridian Health Research Network

The Institutional Review Board of record for the conduct of Protocol PPC-4871-III at this site shall be the Graystone University Institutional Review Board (IRB Registration Number: IRB00012847), which shall maintain oversight responsibility for all human subjects research activities conducted at this site under the Agreement

Title: President Date: June 28, 2023 ACKNOWLEDGMENT OF KEY TERMS By executing this Signature Page, Graystone University Medical Center hereby acknowledges, confirms, and agrees to each of the following key financial, operational, and legal terms as set forth in the Agreement: A

Such fees shall be prorated for any partial year at the end of the trial on a per diem basis calculated as $40,000 divided by 365

Sponsor indemnification for claims arising from defects in the manufacture, formulation, labeling, or packaging of the investigational product (Penterafenib, PPC-4871) shall be uncapped and shall survive termination or expiration of the Agreement; (c) Reciprocal Site Indemnity Obligations

as additional insureds, shall be delivered to the Sponsor within fifteen (15) business days of the execution of this Signature Page to the Master Clinical Trial Agreement